Repligen (RGEN) Stock Price Target 2026

The average analyst price target for Repligen is $180.61, 0.9% above the current price. Of 18 analysts, 15 rate it Buy and 3 Hold. Targets range from $135 to $225. The latest change came on Oct 28, 2026, when RBC Capital raised its price target on Repligen from $185 to $200 and kept an Outperform rating.

The Average Analyst Price Target for Repligen is $180.61.

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

15Buy

3Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$180.61Upside to Avg. PT+0.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Repligen Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$185→$200
Oct 19, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Hold	$145→$180
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$175→$225
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Buy	$195→$225
Jul 30, 2026	Wells Fargo	Evan Stampler	PT Raise	Overweight	$180→$185
Jul 29, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$165→$175
Jul 7, 2026	Benchmark	Robert Wasserman	Upgrade	Hold→Buy	$185
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$150→$160
Jun 3, 2026	HSBC	Sidharth Sahoo	PT Cut	Buy	$170→$150
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	$145
May 15, 2026	RBC Capital	Dan Leonard	Reinstates	Outperform	$160
May 6, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$180→$165
May 6, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$145→$160
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Hold	$165→$145
Apr 17, 2026	Roth Capital	Natalya Davies	Initiate	Buy	$160
Apr 14, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$175→$145
Apr 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$170→$140
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$180→$208
Feb 25, 2026	UBS	Dan Leonard	PT Cut	Buy	$200→$195
Feb 25, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$200→$175